1
|
Jin J, Shan L, Wang M, Liu L, Xu T, Li D, Chen Z, Liu X, Zhang W, Li Y. Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease. Int Heart J 2023; 64:807-815. [PMID: 37704407 DOI: 10.1536/ihj.23-125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 09/15/2023]
Abstract
Dyslipidemia has been widely recognized as a significant risk factor for coronary atherosclerosis disease (CAD). In fact, lipid variability has emerged as a more reliable predictor of cardiovascular events. In this study, we aimed to examine the variability in plasma lipids under two different lipid-lowering regimens (intensive statin therapy versus the combination of conventional-dose statins with ezetimibe). In total, we have retrospectively examined 1275 patients with CAD from January 2009 to April 2019 and divided them into two groups: intensive statin group and conventional-dose statins combined with ezetimibe group. All patients were followed up for at least 1 year. Lipid variability was verified by standard deviation (SD), coefficient of variation (CV), and variability independent of mean (VIM) triple methods. Multiple linear regression and subgroup analyses were performed. In the overall participants, the mean age was 62.3 ± 10.4 years old, and 72.8% were male. Multivariate linear regression analysis indicated that the intensive statin group had lower variability in terms of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol (non-HDL-C) in all SD, CV, and VIM triple methods than statins combined with ezetimibe group (P for all <0.05). Similar results were established in the subgroup analyses based on atorvastatin or rosuvastatin, diabetes mellitus or not, and hypertension or not (P for all < 0.05). Thus, we can conclude that intensive statin therapy could contribute in lowering lipid variability than conventional-dose statins combined with ezetimibe therapy among patients with CAD.
Collapse
Affiliation(s)
- Jinhua Jin
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
| | - Liwen Shan
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
| | - Manjun Wang
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
| | - Lu Liu
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
| | | | - Duanbin Li
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
| | - Zhezhe Chen
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
| | - Xianglan Liu
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
| | - Wenbin Zhang
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
| | - Ya Li
- Department of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province
| |
Collapse
|
2
|
Croyal M, Wargny M, Chemello K, Chevalier C, Blanchard V, Bigot-Corbel E, Lambert G, Le May C, Hadjadj S, Cariou B. Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes. Cardiovasc Diabetol 2022; 21:21. [PMID: 35130909 PMCID: PMC8822824 DOI: 10.1186/s12933-022-01452-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Accepted: 01/20/2022] [Indexed: 12/26/2022] Open
Abstract
Background The identification of circulating biomarkers associated with the risk of type 2 diabetes (T2D) is useful for improving the current prevention strategies in the most at-risk patients. Here, we aimed to investigate the association of plasma apolipoprotein concentrations in prediabetes subjects with the incidence of new-onset T2D during follow-up. Methods In the IT-DIAB prospective study, 307 participants with impaired fasting glucose levels (fasting plasma glucose [FPG]: 110–125 mg/dL) were followed yearly for 5 years. The onset of T2D was defined as a first FPG value ≥ 126 mg/dL during follow-up. Apolipoprotein (apo)A-I, A-II, A-IV, B100, C-I, C-II, C-III, C-IV, D, E, F, H, J, L1, M, and (a) plasma concentrations were determined by mass spectrometry. Correlations between apolipoproteins and metabolic parameters at baseline were assessed by Spearman’s coefficients. Kaplan–Meier curves were drawn using a ternary approach based on terciles and incident T2D. The association between plasma apolipoproteins concentrations and the incidence of T2D was determined using Cox proportional-hazards models. Results During a median follow-up of 5-year, 115 participants (37.5%) developed T2D. After adjustment for age, sex, body mass index, FPG, HbA1c, and statin use, the plasma levels of apoC-I, apoC-II, apoC-III, apoE, apoF, apoH, apoJ, and apoL1 were positively associated with a high risk for T2D. After further adjustment for plasma triglycerides, only apoE (1 SD natural-log-transformed hazard ratio: 1.28 [95% confidence interval: 1.06; 1.54]; p = 0.010), apoF (1.22 [1.01; 1.48]; p = 0.037), apoJ (1.24 [1.03; 1.49]; p = 0.024), and apoL1 (1.26 [1.05; 1.52]; p = 0.014) remained significantly associated with the onset of T2D. Kaplan–Meier survival curves also showed that the lower third of plasma apoE levels (< 5.97 mg/dL) was significantly associated with a lower risk of conversion to T2D (log-rank test, p = 0.002) compared to the middle and upper thirds. Conclusions The plasma apoE levels are positively associated with the risk of T2D in prediabetes subjects, independently of traditional risk factors. The possible associations of apoF, apoJ, and apoL1 with T2D risk also pave the way for further investigations. Trial registration This trial was registered at clinicaltrials.gov as NCT01218061 and NCT01432509 Supplementary Information The online version contains supplementary material available at 10.1186/s12933-022-01452-5.
Collapse
Affiliation(s)
- Mikaël Croyal
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, 8 quai Moncousu, 44000, Nantes, France.,Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, 44000, Nantes, France.,CRNH-Ouest Mass Spectrometry Core Facility, 44000, Nantes, France
| | - Matthieu Wargny
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, 8 quai Moncousu, 44000, Nantes, France.,CHU de Nantes, INSERM CIC 1413, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, Nantes, France
| | - Kevin Chemello
- Université de La Réunion, INSERM UMR 1188 DéTROI, Sainte-Clotilde, France
| | - Chloé Chevalier
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, 8 quai Moncousu, 44000, Nantes, France.,CRNH-Ouest Mass Spectrometry Core Facility, 44000, Nantes, France
| | - Valentin Blanchard
- Departments of Medicine, Centre for Heart Lung Innovation, Providence Healthcare Research Institute, St. Paul's Hospital, University of British Columbia, Vancouver, Canada
| | - Edith Bigot-Corbel
- Department of Biochemistry, CHU Nantes, G et R Laënnec Hospital, Bd Jacques Monod, Nantes, France
| | - Gilles Lambert
- Université de La Réunion, INSERM UMR 1188 DéTROI, Sainte-Clotilde, France
| | - Cédric Le May
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, 8 quai Moncousu, 44000, Nantes, France
| | - Samy Hadjadj
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, 8 quai Moncousu, 44000, Nantes, France.,CRNH-Ouest Mass Spectrometry Core Facility, 44000, Nantes, France
| | - Bertrand Cariou
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, 8 quai Moncousu, 44000, Nantes, France.
| |
Collapse
|
3
|
Liang J, Yi X, Xue M, Chen X, Huang X, Sun Q, Wang T, Zhao C, Yang Y, Gao J, Zhou J, Fan J, Yu M. A retrospective cohort study of preoperative lipid indices and their impact on new-onset diabetes after liver transplantation. J Clin Lab Anal 2020; 34:e23192. [PMID: 31981248 PMCID: PMC7246365 DOI: 10.1002/jcla.23192] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2019] [Revised: 11/17/2019] [Accepted: 12/11/2019] [Indexed: 01/06/2023] Open
Abstract
Background The correlation between preoperative lipid profiles and new‐onset diabetes after transplantation (NODAT) remains relatively unexplored in liver transplant recipients (LTRs). Thus, we aimed to investigate the preoperative lipid profiles in Chinese LTRs and evaluate the different influences of preoperative total cholesterol, total triglycerides (TG), high‐density lipoprotein cholesterol, and low‐density lipoprotein cholesterol on the development of NODAT in both sexes. Methods A total of 767 Chinese LTRs from Zhongshan Hospital were retrospectively evaluated. NODAT was defined according to the American Diabetes Association guidelines; the relationship between each preoperative lipid index and NODAT development was analyzed separately in men and women. Results Pretransplant hypotriglyceridemia was observed in 35.72% of the total LTRs. In men, only the preoperative TG level was significantly associated with incident NODAT after adjusting for potential confounders (hazard ratio 1.37, 95% confidence interval 1.13‐1.66, P = .001). There was a nonlinear relationship between the preoperative TG level and NODAT risk. The risk of NODAT significantly increased with preoperative a TG level above 0.54 mmol/L (log‐likelihood ratio test, P = .043). In women, no significant association was observed. Conclusion Among male LTRs, a higher preoperative TG level, even at a low level within the normal range, was significantly and nonlinearly associated with an increased risk of NODAT.
Collapse
Affiliation(s)
- Jing Liang
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Xilu Yi
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.,Department of Endocrinology and Metabolism, Central Hospital of Songjiang District, Shanghai, China
| | - Mengjuan Xue
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.,Department of Geriatrics and Gastroenterology, Huadong Hospital, Fudan University, Shanghai, China
| | - Xianying Chen
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.,Department of Endocrinology and Metabolism, Hainan Provincial Nong Ken Hospital, Hainan, China
| | - Xiaowu Huang
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.,Key laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.,Shanghai Key Laboratory of Organ Transplantation, Shanghai, China
| | - Qiman Sun
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.,Key laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.,Shanghai Key Laboratory of Organ Transplantation, Shanghai, China
| | - Ting Wang
- Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Chenhe Zhao
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Yinqiu Yang
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Jian Gao
- Center of Clinical Epidemiology and Evidence-based Medicine, Fudan University, Shanghai, China
| | - Jian Zhou
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.,Key laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.,Shanghai Key Laboratory of Organ Transplantation, Shanghai, China
| | - Jia Fan
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.,Key laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.,Shanghai Key Laboratory of Organ Transplantation, Shanghai, China
| | - Mingxiang Yu
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
4
|
Rodriguez-Gutierrez R, Mancillas-Adame LG, Rodríguez-Tamez G, Diaz Gonzalez-Colmenero A, Solis-Pacheco RC, Elizondo-Plazas AS, Santos-Santillana KM, Gonzalez-Sariñana L, Gonzalez-Nava V, Gonzalez-Gonzalez JG. Hypertriglyceridemia and Its Association with HbA1c Test: A Prospective In Vivo Controlled Study. Int J Endocrinol 2019; 2019:4784313. [PMID: 30891069 PMCID: PMC6390253 DOI: 10.1155/2019/4784313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2018] [Accepted: 12/18/2018] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Hypertriglyceridemia and hyperglycemia coexist in 30-60% of patients with diabetes. The impact of hypertriglyceridemia regarding HbA1c assay reliability remains uncertain. Therefore, we conducted a prospective in vivo controlled study with the aim of defining the association between triglyceride levels and HbA1c. METHODS A total of 44 patients with an index-hospital admission diagnosis of diabetic ketoacidosis or hypertriglyceridemia-induced pancreatitis, as a model for acute elevation of triglycerides, were recruited. Blood samples were drawn for the measurement of HbA1c, triglycerides, glucose, and hemoglobin at baseline and subsequently 24 and 48 hours after admission. HbA1c analysis was performed with high-performance liquid chromatography Bio-Rad D10 (NGSP approved). RESULTS All patients completed the study protocol. A difference between mean triglycerides from day 0 (baseline) to day 2 of 1567.2 mg/dL was observed. We found a difference between mean serum HbA1c from days 0 to 2 of 0.09% [1 mmol/mol] (p = 0.004). Moreover, a weak correlation between the mean difference of HbA1c and triglycerides from baseline to day 2 was found to be statistically significant (r = 0.256, p = 0.015). None of these findings, however, are clinically significant. CONCLUSION Triglycerides do not impair the interpretation of HbA1c assay. Patients and clinicians can now be confident that hypertriglyceridemia is not an important factor when interpreting HbA1c results.
Collapse
Affiliation(s)
- Rene Rodriguez-Gutierrez
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
- Universidad Autonoma de Nuevo Leon, Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Monterrey 64460, Mexico
- Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
| | - Leonardo G. Mancillas-Adame
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
- Universidad Autonoma de Nuevo Leon, Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Monterrey 64460, Mexico
| | - Giselle Rodríguez-Tamez
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
- Universidad Autonoma de Nuevo Leon, Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Monterrey 64460, Mexico
| | - Alejandro Diaz Gonzalez-Colmenero
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
| | - Ricardo Cesar Solis-Pacheco
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
| | - Ana Sofia Elizondo-Plazas
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
| | - Karla M. Santos-Santillana
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
| | - Linda Gonzalez-Sariñana
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
| | - Victoria Gonzalez-Nava
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
| | - José Gerardo Gonzalez-Gonzalez
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Endocrinology Division, Department of Internal Medicine, Monterrey 64460, Mexico
- Universidad Autonoma de Nuevo Leon, Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Monterrey 64460, Mexico
- University Hospital “Dr. Jose E. Gonzalez, ” Universidad Autonoma de Nuevo Leon, Research Unit, Monterrey 64460, Mexico
| |
Collapse
|